HistoSonics Enables Histotripsy for Liver Cancer Treatment With GE Team-Up

HistoSonics is upping the ante on liver cancer treatment with the introduction of its HistoSonics Edison System, which will be linked with GE Healthcare’s LOGIQ E10 Series ultrasound platform as a visual guide. The company’s system assists with the application of histotripsy, an ultrasound-driven solution for noninvasively ablating targeted liver tissue. Histotripsy is a pioneering effort in nonthermal and nonionizing ablation technology, guided by real-time imaging.

GE’s LOGIQ E10 Series will be distributed by HistoSonics, offering clinicians unmatched visualization for procedure planning as well as monitoring and instant post-treatment verification. The solutions will be enabled for HistoSonics’ U.S. and European trials under the banner #HOPE4LIVER; the trials are set to test the safety and efficiency of histotripsy for treating primary and metastatic liver tumors. HistoSonics’ Vice President of R&D, Joshua Stopek, said, "We've developed a very collaborative relationship with GE Healthcare and look forward to expanding our efforts to realize the full potential of histotripsy across clinical applications, specialties, and care settings.”

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now

Based on early clinical and preclinical data, a major benefit of histotripsy is providing the ability to preserve critical structures like the liver capsule and larger vessels through real-time tissue destruction monitoring by physicians. Operating at a subcellular level, this technique mechanically eliminates and liquifies targeted tissues while fostering treatment zones that guarantee equal treatment for all areas of the tumor.